Stephen Tam, MD
Internal Medicine · Las Vegas, NVNPI 1689738478
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,852 of the $5,003 with a category attached, or 77.0%. Modernatx, Inc. accounts for 68.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $3,400 and has fallen 93.5% since, to $219 in 2025. Among internal medicine clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $131.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$3K
- AstraZeneca$1K
- E.r. Squibb & Sons, L.L.C.$219
- Abbott$47
- Dexcom, Inc.$37
- Genentech USA, Inc.$23
- plus $20 from 1 others
Across 72 payments — averaging $13,120 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$749K
- Teva Pharmaceuticals USA, Inc.$127K
- Vertex$41K
- F. Hoffmann-la Roche AG$15K
- Genentech, Inc.$12K
What the payments were for
- Travel & lodging$3,85277%
- Food & beverage$1,15123%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 20 | $3,400 |
| AstraZeneca | 10 | $1,255 |
| E.r. Squibb & Sons, L.L.C. | 1 | $219 |
| Abbott | 3 | $47 |
| Dexcom, Inc. | 2 | $37 |
| Genentech USA, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$951
How this compares
$5,003 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,035 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $376 |
| Gabapentin | 27 | $262 |
| Lisinopril | 31 | $245 |
| Atorvastatin Calcium | 19 | $134 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $129 |
| Montelukast Sodium | 13 | $115 |
| Pantoprazole Sodium | 13 | $66 |
| Ibuprofen | 14 | $66 |
| Trazodone Hcl | 14 | $39 |
| Furosemide | 14 | $33 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.